Posts for Ticker ‘CI’

BioHealth Business Daily (CI, AET, MYL, JAZZ, PTIE, GSK, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that are covered in-depth today at BioHealthInvestor.com:

Cigna corp. (NYSE: CI), Aetna Inc. (NYSE: AET), and other managed care companies are rising despite making health care reform concessions, as shareholders see they have a seat at the bargaining table.

Mylan Inc. (NASDAQ: MYL) has received FDA approval for a generic version of an AstraZeneca (AZN) prostate cancer drug — a rather unusual new generic.

Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) shares are up more than 25 percent after the company took steps to ease a cash crunch that had curtailed drug development.

King Pharmaceuticals (KG) and Pain Therapeutics (PTIE) said  they expect to resubmit a new drug application in mid-2010, slightly later than anticipated.

GlaxoSmithKline (NYSE: GSK) announced a positive study on its Cervarix vaccine, although it’s unclear if the company can play catch-up to Merck & Co.’s (NYSE: MRK) Gardasil.

See our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Health Care Companies Play Let’s Make A Deal (CI, AET, HUM, UNH, WLP, CVH, THC, HLS)

biotech

Managed health care company stocks are rising Tuesday despite press reports that hospitals will contribute $155 billion over 10 years toward insuring the nearly 50 million Americans who do not have coverage.

The cuts would largely come from the amount the insurers receive as reimbursement from Medicare and Medicaid.

Shares of Cigna corp. (NYSE: CI), Aetna Inc. (NYSE: AET), Humana Inc (NYSE: HUM), and UnitedHealthGroup Inc (NYSE: UNH) each are up more than 4 percent in early trading, with shares of WellPoint Inc. (NYSE: WLP) and Coventry Health Care Inc. (CVH) also on the rise.

Read more at BioHealth Investor….

Medicare Winners Under New Healthcare Plans (MRK, PFE, AET, CI, CVH, HUM, UNH, WLP)

Everyone is trying to figure out who the winners and losers are likely to be under a watered-down healthcare program under the Obama administration and with a Democratic Congress.  What is certain is that changes to the old way of healthcare are coming, yet the uncertainty is becoming just how far away from the existing model this will get.  Mike Tarsala contributed a a brief round of explanations for the way this will likely impact drug giants Merck & Co. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE).  There is also a solid take on how companies like Humana Inc (NYSE: HUM), Coventry Health Care Inc. (NYSE: CVH), Cigna corp. (NYSE: CI), United Health (NYSE: UNH), WellPoint Inc. (NYSE: WLP) and Aetna Inc (NYSE: AET) are likely to be viewed.

More details of this can be seen at BioHealthInvestor.com.

Cramer’s Obama Healthcare Winner: WellPoint (WLP, CI, UNH, AET)

Cramer ImageJim Cramer came out with a healthcare maintenance  stock tonight on CNBC’s MAD MONEY which he thinks will survive and perhaps thrive under the Obama healthcare plan.  His pick in the healthcare maintenance sector is WellPoint Inc. (NYSE: WLP).  Cramer said he has not been in support of Cigna (NYSE: CI), UnitedHealth (NYSE:  UNH) and Aetna (NYSE: AET).  He also said he won’t be going there.

Read More »

The 52-Week Low Club (HIG)(CI)(AVP)(GLBL)(SYMC)(EXPE)

Sad_clownHartford Financial (HIG) Big analyst downgrade. Plunges to $8.23 from 52-week high of $98.70.

CIGNA (CI) Profit drops 53%. Stock off to $15.08 from 52-week high of $56.98.

Avon (AVP) Weak guidance. Falls to $19.85 from 52-week high of $45.34.

Global Industries (GLB) Bad earnings. Analyst downgrade. Daily double. Off to $2.27 from 52-week high of $27.06.

Symantec (SYMC) Misses on earnings and give poor outlook. Moves down to $11.85 from 52-week high of $22.80.

Expedia (EXPE) Big drop-off in its core market–travel.. Sells down to $9.66 from 52-week high of $34.66.

Douglas A. McIntyre

Top 10 Pre-Market Analyst Calls (COF, CI, CS, GPS, THQI, TIF, UNH, WBD, YHOO, ZUMZ)

These are the top analyst upgrades and downgrades that 247WallSt.com is focusing on in pre-market trading this Tuesday morning:

  • Capital One (NYSE: COF) downgraded to Underperform at FBR.
  • CIGNA (NYSE: CI) raised to Outperform at Credit Suisse.
  • Credit Suisse Group (NYSE: CS) downgraded to Neutral at UBS.
  • Gap Inc. (NYSE: GPS) downgraded to Hold at Citigroup.
  • THQ Inc. (NASDAQ: THQI) raised to Buy at Citigroup.
  • Tiffany & Co. (NYSE: TIF) downgraded to Perform at Oppenheimer.
  • UnitedHealth (NYSE: UNH) downgraded to Neutral at Credit Suisse.
  • Wimm-Bill-Dann (NYSE: WBD) raised to Buy at Citigroup.
  • Yahoo! (NASDAQ: YHOO) raised to Buy at Citigroup.
  • Zumiez (NASDAQ: ZUMZ) downgraded to Perform at Oppenheimer.

Jon C. Ogg
March 25, 2008

Jon Ogg produces the Special Situation Investing Newsletter and can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Top 10 Pre-Market Analyst Calls (CI, FPL, GPS, HA, LEH, MON, POT, UPL, WFC, XRTX)

These are the top ten analyst calls we are looking at this Monday morning in pre-market trading:

  • CIGNA (NYSE: CI) raised to Buy at UBS.
  • FPL Group (NYSE: FPL) raised to Overweight at Lehman.
  • Gap Inc. (NYSE: GPS) Cut to Neutral at UBS.
  • Hawaiian Airlines, Inc. (NYSE: HA) raised to Outperform at Bear Stearns.
  • Lehman Brothers (NYSE: LEH) downgraded to Perform from Outperform at Oppenheimer.
  • Monsanto (NYSE: MON) raised to Buy at UBS.
  • Potash Corp. opf Saskatchewan (NYSE: POT) raised to TOP PICK at RBC Capital.
  • Ultra Petroleum (NYSE: UPL) started as Outperform at Credit Suisse.
  • Wells Fargo (NYSE: WFC) downgraded to Underperform at Robert W. Baird.
  • Xyratex (NASDAQ: XRTX) raised to Outperform at Wachovia.

Jon C. Ogg
March 24, 200

Bleak House: Despair On The 52-Week Low List (GE)(VZ)(GOOG)(C)

Those rummaging through the garbage of 52-week low lists are usually bottom-fishing investors or desperate CEOs. But, the list is so broad that it has become a tableau of the market as a whole, especially the breadth of the market’s decline across almost every industry.

Not a single person in the world is surprised that financials like Bear Stearns (NYSE: BSC), Goldman Sachs (NYSE: GS), Citigroup (NYSE: C), and Cigna (NYSE: CI) hit bottoms last weak. Over in the car business both Ford (NYSE: F) and GM (NYSE: GM) dropped to lows. Perhaps more surprising Toyota (NYSE: TM), the world’s most successful car company, came close. Given its vast resources and cash position, that news said more than the GM or Ford numbers did.

Airlines, as expected, were crushed. AMR (NYSE: AMR) was at the front of the Charge of the Light Brigade. Retail would also expected to be down and many stocks in that sector were at bottom including the previously popular Best Buy (NYSE: BBY).

The newspaper industry, the dying art of people reading information off something other than a computer screen, also had a number of lows, led by Gannett (NYSE:GCI) and McClatchy NYSE: MNI).

If the painful trend ended here, with these sectors, it would at least be in line with what might be expected in troubled industries in a slowing economy. But, it does not.

Communications companies, in both telecom and cable, hit bottoms. Verizon (NYSE: VZ) did the limbo. So did Comcast (NYSE: CMCSA). These firms are known for the breadth of their businesses, astonishing cash flow, and iron-clads balance sheets. By the market’s logic, that data meant little.

Tech also was sucked under. That included some of the first class companies in the sector like Adobe (NYSE: ADBE), Nvidia (NASDAQ: NVDA), and Infosys (NASDAQ: INFY). This is worth some analysis. NVDA is expected to have a 37% increase in revenue this quarter and EPS that will move from $.28 last year to $.39. The company is down almost 50% from its 52-week high. Analysts expect Infosys revenue to be up 32% for the current period. Wall St.’s whirlpool is taking under strong companies as it pulls down the weak.

The same might be said for Big Pharma. Bristol-Myers (NYSE: BMY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK) all posted lows. The markets have been worried about their product pipelines, but that issue has not become more acute recently and these companies are still, for the time being, cash machines. Most have yields above 1.5% and some are much higher.

Deep trouble has also extended to the internet content business which has done well since the tech crash of 2000. Last week TheStreet.com (NASDAQ: TSCM), CNET (NASDAQ: CNET), and IACI (NASDAQ: IACI) dropped to 52-week lows. Given the low fixed costs that these companies sport along with pristine balance sheets, they would seem to be due some break.

Older line media companies, which have said they are not seeing any profound slowing in their businesses we sold off in a near panic dropping CBS (NYSE: CBS) and Time Warner (NYSE: TWX) to the lowest end of their charts.

Alternative energy stocks, not so long ago darlings, pushed to new bottoms. Verasun (NYSE: VSE) and Trina Solar (NYSE: TSL) could not hold on. Even the high cost of oil could not give them buoyancy

The most stunning part of all of this is the capitulation of the blue chips. Boeing (NYSE: BA) hit a 52-week low. The Air Force contract it lost is not worth enough spread over its life to do any real damage. Google (NASDAQ: GOOG) bottomed telling Wall St. that a company with 60% market share and 50% earnings growth was not worth some premium.

And, General Electric (NYSE: GE), the market’s poster boy for American services and industry, hit its low for 52-weeks. It has not backed off its robust projections for EPS improvement. It credit ratings remain the envy of almost every other company in the world. Its business and geographic diversity are supposed to make it the business equivalent of Plato’s ideal of the perfect state.

To look for investor concern about how deep and long the recession will be, the 52-week low list may be the most telling set of numbers available. It is an unusually broad and deep data-base. It is about money, and without emotion.

The list is saying that things are worse off than they seem.

Douglas A. McIntyre

The 52-Week Low Club (HUM)(WLP)(CI)(S)

Humana (HUM) Health insurers pulled down by bad news at WellPoint. Falls to $42.85 from 52-week high of $88.10.

Wellpoint (WLP) Profit warning. Drops to $46.66 from 52-week high of $90.

CIGNA Corporation (CI) Insurance whirlpool is a catch-all. Down to $36.75 from 52-week high of $57.61.

Sprint Nextel (S) Further concerns about earnings and subscriber defections. No M&A deal appears to be in the offing. Sells down to $5.55 from 52-week high of $23.42.

Suntech Power (STP) Company to offer $425 million in new notes. Shares tumble to $28.91 from 52-week high of $90.

Jones Soda (JSDA) Fourth quarter loss. Drops to $2.65 from 52-week high of $32.60.

Altair Nanotechnologies (ALTI) Still falling days after CEO leaves and stock gets downgraded.

Douglas A. McIntyre

Goldman Sachs Conviction Buy List Changes (CI, WLP, CNH)

Goldman Sachs is making a change to its CONVICTION BUY LIST this morning.  The firm is adding CIGNA (NYSE: CI) and dropping WellPoint (NYSE: NYSE: WLP) from the list.  Both stocks are still maintained as officially being BUY rated there, but Goldman Sachs sees a near-term opportunity in CIGNA shares.  In fact, the 6-month price target on CIGNA gives an implied upside of 30%.

CNH Global N.V. has also been booted off of the CONVICTION BUY LIST, although that is because of a stop-loss feature.  The firm is maintaining a BUY rating and says it is not a seller at current levels.  The stock is down some 22% since its addition to the list on November 27, 2007.

Jon C. Ogg
February 8, 2008

Pre-Market Stock News (November 27, 2007)

Below is a snapshot of much of the pre-market news moving individual stocks this morning:

  • Activision (ATVI) raised guidance on Guitar Hero III sales; stock up 8% pre-market.
  • Barrier Therapeutics (BTRX) announced positive results of higher dose escalation clinical safety study with pramiconazole.
  • Casual Male (CMRG) indicated lower after missing earnings and guiding lower.
  • CIGNA (CI) is acquiring Great-West Healthcare for $1.5 Billion.
  • Citigroup (C) sold a $7.5 Billion stake to Abu Dhabi Fund.
  • GlobalSantaFe (GSF) has received a subpoena from the SEC seeking documents related to the company’s ongoing internal investigation.
  • Hydrogenics (HYGS) received a $1.7 million order for three fuel cell hybrid MiniBuses for an Expo in Spain.
  • Osiris Therapeutics (OSIR) announced positive one-year data from Chondrogen trial for knee repair in its preparation of adult stem cells formulated for direct injection into the knee.
  • Penford Corp (PENX) announced a 2 Million share common stock offering, although this was under the existing shelf offering.
  • Pharmacopeia (PCOP) and GlaxoSmithKline identified two new additional lead compounds that will trigger milestone payment of $1 million to Pharmacopeia.
  • Qiao Xing (XING) telegraphss medium and long-term business plans and will continue to take steps to ensure growth of 20% to 30% per year for the next 5-years.
  • Sepracor (SEPR) announced the completion of its SEC investigation and no enforcement action was recommended.
  • Smith & Nephew (SNN) announces precautionary knee recall.
  • Staples (SPLS) $0.42 EPS vs $0.40 est.
  • Tech Data (TECD) $0.73 EPS vs $0.60 est. (unsure if comparable) sales guidance for Q4 looks a tad light.
  • Tenet Healthcare (THC) entered into a new national insurance coverage agreement with UnitedHealthcare (UNH).

Jon C. Ogg
November 27, 2007

Jon Ogg produces the 24/7 Wall St. Special Situation Investing Newsletter; he does not own securities in the companies he covers.

Pre-Market Earnings Gappers (November 2, 2007)

(ALY) Allis-Chalmers $0.37 EPS vs $0.36 est.
(ASVI) A.S.V. Inc. $0.13 EPS vs $0.19 est.
(BEBE) bebe stores traded up 3% despite slight revenue miss.
(CBB) Cincinnati Bell $0.09 EPS vs $0.08 est.
(CI) CIGNA $1.14 EPS vs $0.93 est.
(DUK) Duke Energy $0.48 EPS vs $0.39 est.
(ENCY) Encysive -$0.32 EPS vs -$0.31 est.
(ERTS) Electronic Arts trading up 3% after beating earnings.
(GYI) Getty Images traded up 5% after earnings.
(HAIN) Hain Celestial rose almost 5% after beating earnings expectations.
(HIMX) HIMAX trading up 7% after earnings.
(IP) International Paper $0.57 EP vs $0.57 est.
(ITRI) Itron trading down 11% after earnings.
(LVS) Las Vegas Sands trading down $16+ to $109 pre-market on net loss.
(MSO) Martha Stewart Enterprises -$0.08 EPS vs -$0.13 est.
(NI) NIsource $0.08 EPS vs $0.10 est.
(NTLS) NETELOS $0.18 EPS vs $0.14 est.
(NYX) NYSE $0.76 EPS vs. $0.73 est.
(OMG) OM Group $1.30 EPS vs $1.17 est.
(RDEN) Elizabeth Arden $0.04 EPS vs -$0.05 est.; sees Q2 $1.11-1.16 vs $1.21 est.
(SGMS) Scientific Games down 4% after earnings.
(SYNA) Synaptics traded up 10% after beating earnings expectations.
(VCLK) ValueClick trading down 0.5% after lackluster earnings.
(VIA) Viacom $0.65 vs 0.60

Pre-Market Analyst Calls (September 27, 2007)

AET started as Outperform at Wachovia.
CI started as mkt perform at Wachovia.
CEO cut to Neutral at Goldman Sachs.
EQ cut to Underweight at Morgan Stanley.
GME cut to Neutral at UBS.
HNT started as mkt perform at Wachovia.
KND raised to Mkt Perform at Wachovia.
LEVP started as outperform at CIBC.
MGA raised to outperform at CIBC.
MOGN started as Outperform at FBR.
PUK raised to outperform at Bear Stearns.
RMD cut to Neutral at UBS.
SBUX cut to Sell at B of A.
TIBX started as Neutral at Sun Trust Robinson Humphrey.
WSTL raised to Outperform at RW Baird.

Jon C. Ogg
September 27, 2007

Earlybird Analyst Calls (June 19, 2007)

ACLI cut to Hold at Deutsche Bank.
ACOR raised to Buy at B of A.
AGO cut to Underweight at JPMorgan.
ANAD started as Buy at Oppenheimer.
ANET cut to Neutral at Baird.
ATHR started as Buy at Oppenheimer.
AV cut to Mkt Perform at JMP Securities.
BAC raised to Buy at UBS.
BEAS cut to Neutral at UBS.
CHD started as Buy at Sun Trust Robinson Humphrey.
CI raised to Neutral at B of A.
EGLE started as Neutral at JPMorgan.
EPIC started as Buy at Sun Trust Robinson Humphrey.
GNK started as Overweight at JPMorgan.
GNTX raised to Buy at B of A.
KNX raised to Outperform at Wachovia.
LCC raised to Neutral at UBS.
MCHP cut to Mkt Perform at Piper Jaffray.
QMAR started as Neutral at JPMorgan.
SDXC started as Buy at Kaufman Bros.
SKH started as Buy at Jefferies.
SRE raised to Buy at Citigroup.
TZIX started as Buy at Deutsche Bank.
WERN raised to Outperform at Wachovia.
YRCW cut to Mkt Perform at Wachovia.

Jon C. Ogg
June 19, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Cramer’s #3 & #2 Buybacks=Buyouts Picks

Cramer has a new method for predicting takeovers.  Four of the fourteen largest buybacks have either been taken over or have agreed to be taken over in the last few months.  Cramer thinks the other 10 are great buyback targets as well.  Cramer has 3 picks out of these 10.  His #1 pick will be after the Lightning Round.  He also said that he is only focusing on buyout candidates that he thinks are good all on their own.

Cigna (CI) is on the list but he’s already highlighted it recently.  Sonic (SONC) and Cracker Barrel (CBRL) would have been on Cramer’s list except that he thinks they are too vulnerable to consumer spending and too vulnerable to higher gasoline prices.

The #3 pick is United Stationers (USTR-NASDAQ) which has bought back 20% of its outstanding shares.  The company should have improving margins and there are only three analysts covering the stock.   

The #2 pick is Brinks (BCO-NYSE) that bought back 21% of its stock.  He thinks the fundamentals are great on this one.  This one is a home security play and a play for securely transporting financial and luxury goods.

What is funny is that since Cramer hates ETF’s so much, he neglected to tell you about PowerShares Buyback Achievers Portfolio (AMEX:PKW).  This is an ETF that actively invests in companies who are buying back shares.  As far as which of these are good and bad, United Stationers is one that has many competitors that go through periods where they look good and bad.  They are ultra-sensitive to economic cycles and business spending.  But Brinks on the other hand is one that is solid.  The stock is up on its 52-week highs, but here is thing: this company already transports massive amounts of luxury goods that the millionaires and billionaires already use.  This one makes sense, and it would have been a perfect play for Berkshire Hathaway earlier if the size was larger than $3 Billion.

Jon C. Ogg
May 7, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in any of the companies he covers.